Skip to content

Nutrition ALD: Effect of screening tool for malnutrition in advanced liver disease.

Nutrition ALD: Effect of screening tool for malnutrition in advanced liver disease: a patient-driven, value-based approach to medical nutrition therapy.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12624000472572
Enrollment
50
Registered
2024-04-16
Start date
2023-05-02
Completion date
2024-01-18
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary aim of this research is to develop and examine the acceptability, feasibility and effectiveness of a malnutrition screening tool encompassing physiological, psychosocial, emotional, financial, and cultural determinants of malnutrition for patients with ALD (with or without ascites).

Interventions

Aiming to develop and examine the acceptability, feasibility and effectiveness of a malnutrition screening tool encompassing physiological, psychosocial, emotional, financial, and cultural determinants of malnutrition for patients with ALD (with or without ascites). The tool will consist of yes/no questions relating to weight, appetite and physical symptoms along with non physiological factors affecting oral intake. Patients will be seen during a once only face to face (or via phone) standard

Aiming to develop and examine the acceptability, feasibility and effectiveness of a malnutrition screening tool encompassing physiological, psychosocial, emotional, financial, and cultural determinants of malnutrition for patients with ALD (with or without ascites). The tool will consist of yes/no questions relating to weight, appetite and physical symptoms along with non physiological factors affecting oral intake. Patients will be seen during a once only face to face (or via phone) standard care appointment at one regional and one metropolitan hospital liver service outpatient clinic, day stay or acute care inpatient admission. Data will be captured and stored using Redcap. Baseline Data: Baseline characteristics including measures of nutritional status (including anthropometry and bioimpedance monitoring) will be collected on each patient participant. Measurements will include Child Pugh classification and Charlson Comorbidity Index (CCI). Child Pugh classification will be calculated by existing gastroenterology clinicians from patient medical records. CCI will be collected via administrative data extract of patients’ electronic medical records during statistical analysis. Any data will be collected by the research team after the participants have provided informed consent. Intervention: A 30 minute pre-trial interview will be conducted consisting of semi-structured interviews at the first point of contact in standard care clinics. This may be weeks to months in advance of the intervention pending clinic appointments. At the following standard care clinic appointment all screening tools and assessments will be conducted in one 30 minute session. The Integrated Palliative care Outcome Scale (IPOS) will assess the physiological, psychosocial, emotional, financial, and cultural impacts of nutrition (or malnutrition) on health and quality of life for each participant, this tool will take less than 15 minutes to complete. Each participant will then complete four malnutrition screening tools: Royal Free Hospital-Nutrition Prioritising Tool (RFH-NPT), Malnutrition Screening Tool (MST), Patient Generated-Subjective Global Assessment Short Form (PGSGASF) and our novel malnutrition screening tool. Each screening tool takes approximately 5 minutes or less to complete. The Subjective Global Assessment (SGA) will be completed as per standard care practice with the research Dietitian and/or Dietitian Honours student.

Sponsors

Associate Professor Dr Katie Wynne
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Other
Primary purpose
Diagnosis
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients aged 18 years and over with Child Pugh B or C liver disease.

Exclusion criteria

Those unable to provide consent.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026